DoW Vision, Clinical Trial Award

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

DoW Vision, Clinical Trial Award

Issuing agency

Defense Health Agency Contracting Activity - DHACA (Department of Defense)

Opportunity number

HT942526VRPCTA

Funding type

Grant

Funding purpose

Science and Technology and other Research and Development

Status

Open (posted)

Application deadline

Closes November 12, 2026(13 days left)

Published award range

Not published by the agency

Estimated total program funding

$2,600,000

Expected number of awards

1

Cost sharing or match required

No

Eligible applicants (official categories)

• Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

12.420

Official source

View on Grants.gov ↗

Application URL

www.grants.gov/search-results-detail/362183 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 362183 · Funding opportunity number HT942526VRPCTA

Posted

May 5, 2026 · Source last updated May 6, 2026

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

83% of key fields published by the sourceNot published: published funding range, eligibility criteria text.

Record confidence

highVerified against the official source; key fields present; no open issues.

Description (from the official listing)

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: · For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. · Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. · Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Agency contact

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
help@eBRAP.org